Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Remon

Showing results (41-50 of 184) with videos related to

Pageof 19
Sort By:
Immunotherapy|July 31, 2019
Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?Elie Rassy, Laura Mezquita, Jordi Remon, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2011
SEOM guidelines for the treatment of malignant pleural mesotheliomaPilar Lianes, Jordi Remon, Isabel Bover, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapyCamille Mazza, Jordi Remon, Charles Honoré, et al.
Cancer Treatment Reviews|March 20, 2021
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancerJordi Remon, Daniele Pignataro, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLCLizza E L Hendriks, Jordi Remon, Martin Reck
European Journal of Cancer (Oxford, England : 1990)|November 1, 2023
Are we ready to escalate or de-escalate immune treatment strategies in NSCLC based on liquid biopsy data?Jordi Remon, Alvaro Lopez, David Planchard, et al.
Translational Lung Cancer Research|May 19, 2020
Cystic brain metastases and <i>RET</i> fusion in lung cancerJordi Remon, Francesco Facchinetti, Benjamin Besse, et al.
Translational Lung Cancer Research|July 18, 2020
First-line immune-chemotherapy combination for squamous NSCLC is already a realityLizza E L Hendriks, Jessica Menis, Jordi Remon
The Lancet. Respiratory Medicine|August 12, 2019
Treatment duration of checkpoint inhibitors for NSCLCJordi Remon, Jessica Menis, Sandrine Aspeslagh, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2023
Does perioperative immunotherapy reduce the risk of second primary cancers?Marco Tagliamento, Jordi Remon, David Planchard, et al.
Pageof 19

Showing results (41-50 of 184) with videos related to

Sort By:
Pageof 19
Immunotherapy|July 31, 2019
Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?Elie Rassy, Laura Mezquita, Jordi Remon, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2011
SEOM guidelines for the treatment of malignant pleural mesotheliomaPilar Lianes, Jordi Remon, Isabel Bover, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapyCamille Mazza, Jordi Remon, Charles Honoré, et al.
Cancer Treatment Reviews|March 20, 2021
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancerJordi Remon, Daniele Pignataro, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2022
Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLCLizza E L Hendriks, Jordi Remon, Martin Reck
European Journal of Cancer (Oxford, England : 1990)|November 1, 2023
Are we ready to escalate or de-escalate immune treatment strategies in NSCLC based on liquid biopsy data?Jordi Remon, Alvaro Lopez, David Planchard, et al.
Translational Lung Cancer Research|May 19, 2020
Cystic brain metastases and <i>RET</i> fusion in lung cancerJordi Remon, Francesco Facchinetti, Benjamin Besse, et al.
Translational Lung Cancer Research|July 18, 2020
First-line immune-chemotherapy combination for squamous NSCLC is already a realityLizza E L Hendriks, Jessica Menis, Jordi Remon
The Lancet. Respiratory Medicine|August 12, 2019
Treatment duration of checkpoint inhibitors for NSCLCJordi Remon, Jessica Menis, Sandrine Aspeslagh, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2023
Does perioperative immunotherapy reduce the risk of second primary cancers?Marco Tagliamento, Jordi Remon, David Planchard, et al.
Pageof 19